HD-med: A longitudinal, observational study to assess medication use, medication efficacy and the role of pharmacogenetics in Huntington*s Disease.

Recruiting

Conditions: Huntington's Disease
Huntington's chorea (outdated terminology)
10083624
10028037

Registration Number: NL-OMON55123

Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 391

Inclusion Criteria

- A capacitated individual, aged >= 18 years.
- Genetically confirmed CAG-repeat expansion of >= 36 in the Huntingtin gene.
- Either about to start with prescribed medication related to HD or already
using one or more HD related drugs. HD-related drugs are drugs considered to
treat symptoms that either are related to manifest HD or are prescribed in
pre-motor manifest or prodromal HD stage for symptoms that may be attributed to
HD.
- Sufficient knowledge of the Dutch language to understand the subject
information letter and sign the IC.

Exclusion Criteria

Any medical condition, in the view of the investigator, which might endanger
subject*s safety and/or satisfactory participation in the study.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Percentage definite prescription changes in HD gene carriers with a divergent<br /><br>PGx CYP2C19 or CYP2D6 phenotype (poor and ultra-rapid metabolizers) versus<br /><br>those with a PGx phenotype in more normal range (extensive and intermediate<br /><br>metabolizers). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters/endpoints:<br /><br>- Overview of medication use by HD gene carriers in one year.<br /><br>- Accuracy of a one-year medication diary compared to pharmacy medication<br /><br>history surveys.<br /><br><br /><br>Exploratory study parameters/endpoints<br /><br>- Identify potentially new genetic polymorphisms with pharmacogenetic action in<br /><br>HD gene carriers.</p><br>